Passage Bio, a Philadelphia gene therapy startup spun out of the University of Pennsylvania, is set to go public Friday. The company plans to sell 7.4 million shares of its common stock at between $16 and $18 per share, according to documents it filed with the Securities and Exchange Commission.
Read more on the Philadelphia Business Journal